A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease

Bibliography

• SELKOE DJ: Alzheimer’s disease is a synaptic failure. Science (2002) 298(5594):789-791.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Defining molecular targets to prevent Alzheimer’s disease. Arch. Neurol. (2005) 62(2):192-195.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ, SCHENK D: Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. (2003) 43:545-584.
   PubMed Web of Science ®Google Scholar
• WIECH K, KIEFER RT, TOPFNER S et al.: A placebo-controlled randomized crossover trial of the N-methyl-d-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth. Analg. (2004) 98(2):408-413.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT, MARAGOS WF, ALBIN RL, PENNEY JB, YOUNG AB: Glutamate transmission and toxicity in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12(4):421-430.
   PubMed Web of Science ®Google Scholar
• AMADORO G, CIOTTI MT, COSTANZI M, CESTARI V, CALISSANO P, CANU N: NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc. Natl. Acad. Sci. USA (2006) 103(8):2892-2897.
   PubMed Web of Science ®Google Scholar
• RIEDERER P, HOYER S: From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J. Neural Transm. (2006) 113(11):1671-1677.
   PubMed Web of Science ®Google Scholar
• LIPTON SA: The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. (2005) 2(2):155-165.
   PubMedGoogle Scholar
• LIPTON SA: Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. (2006) 5(2):160-170.
   PubMed Web of Science ®Google Scholar
• LIPTON SA, CHEN HS: Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. (2004) 11(1):18-20.
   PubMed Web of Science ®Google Scholar
• ROGAWSKI MA, WENK GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. (2003) 9(3):275-308.
   PubMedGoogle Scholar
• LI L, SENGUPTA A, HAQUE N, GRUNDKE-IQBAL I, IQBAL K: Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. (2004) 566(1-3):261-269.
   PubMed Web of Science ®Google Scholar
• KIMURA M, KOMATSU H, OGURA H, SAWADA K: Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci. Lett. (2005) 391(1-2):17-21.
   PubMed Web of Science ®Google Scholar
• MIGUEL-HIDALGO JJ, ALVAREZ XA, CACABELOS R, QUACK G: Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. (2002) 958(1):210-221.
   PubMed Web of Science ®Google Scholar
• SEIF El NASR M, PERUCHE B, ROSSBERG C, MENNEL HD, KRIEGLSTEIN J: Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. (1990) 185(1):19-24.
   PubMed Web of Science ®Google Scholar
• WENK GL, ZAJACZKOWSKI W, DANYSZ W: Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav. Brain Res. (1997) 83(1-2):129-133.
   PubMed Web of Science ®Google Scholar
• TREMBLAY R, CHAKRAVARTHY B, HEWITT K et al.: Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J. Neurosci. (2000) 20(19):7183-7192.
   PubMed Web of Science ®Google Scholar
• TROTTI D, GIBB SL: Glutamate transporters. In: Neurodegenerative diseases: neurobiology, pathogenesis, and therapeutics. Beal MF, Lang AE, Ludolph AC (Eds), Cambridge University Press, Cambridge, UK (2005):57-64.
   Google Scholar
• IKONOMIDOU C, TURSKI L: Excitotoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases. In: Neurodegenerative diseases: neurobiology, pathogenesis, and therapeutics. Beal MF, Lang AE, Ludolph AC (Eds), Cambridge University Press, Cambridge, UK (2005):44-56.
   Google Scholar
• HARRIS ME, HENSLEY K, BUTTERFIELD DA, LEEDLE RA, CARNEY JM: Direct evidence of oxidative injury produced by the Alzheimer’s beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. (1995) 131(2):193-202.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, GOODMAN Y: Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. (1995) 676(1):219-224.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int. J. Geriatr. Psychiatry (2003) 18(Suppl. 1):S23-S32.
   PubMed Web of Science ®Google Scholar
• WOODSIDE BL, BORRONI AM, HAMMONDS MD, TEYLER TJ: NMDA receptors and voltage-dependent calcium channels mediate different aspects of acquisition and retention of a spatial memory task. Neurobiol. Learn. Mem. (2004) 81(2):105-114.
   PubMed Web of Science ®Google Scholar
• HARNEY SC, ROWAN MJ, ANWYL R: Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering. J. Neurosci. (2006) 26(4):1128-1132.
   PubMed Web of Science ®Google Scholar
• WANG Q, ROWAN MJ, ANWYL R: Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. (2004) 24(27):6049-6056.
   PubMed Web of Science ®Google Scholar
• FRANKIEWICZ T, POTIER B, BASHIR ZI, COLLINGRIDGE GL, PARSONS CG: Effects of memantine and MK-801 on NMDA-induced currents in cultured neurons and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. (1996) 117(4):689-697.
   PubMed Web of Science ®Google Scholar
• ZAJACZKOWSKI W, FRANKIEWICZ T, PARSONS CG, DANYSZ W: Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology (1997) 36(7):961-971.
   PubMed Web of Science ®Google Scholar
• FRANKIEWICZ T, PARSONS CG: Memantine restores long-term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology (1999) 38(9):1253-1259.
   PubMed Web of Science ®Google Scholar
• FRANKIEWICZ T, PILC A, PARSONS CG: Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology (2000) 39(4):631-642.
   PubMed Web of Science ®Google Scholar
• SCHMITT FA, WICHEMS CH: A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim. Care Companion J. Clin. Psychiatry (2006) 8:158-169.
   PubMedGoogle Scholar
• GALASKO D, SCHMITT F, THOMAS R, JIN S, BENNETT D; ALZHEIMER’S DISEASE COOPERATIVE STUDY: Detailed assessment of activities of daily living in moderate-to-severe Alzheimer’s disease. J. Int. Neuropsychol. Soc. (2005) 11(4):446-453.
   PubMed Web of Science ®Google Scholar
• SCHMITT FA, ASHFORD W, ERNESTO C et al.: The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s disease Cooperative Study. Alzheimer Dis. Assoc. Disord. (1997) 11(Suppl. 2):S51-S56.
   PubMed Web of Science ®Google Scholar
• REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ; MEMANTINE STUDY GROUP: Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. (2003) 348(14):1333-1341.
   PubMed Web of Science ®Google Scholar
• REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ: A 24-week open-label extension study of memantine in moderate-to-severe Alzheimer’s disease. Arch. Neurol. (2006) 63(1):49-54.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, FARLOW MR, GROSSBERG GT, GRAHAM SM, MCDONALD S, GERGEL I; MEMANTINE STUDY GROUP: Memantine treatment in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 291(3):317-324.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, PORITIS N: Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry (1999) 14(2):135-146.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, GRAHAM SM, LEE G: Efficacy and tolerability of memantine in nursing home patients with moderate-to-severe dementia of the Alzheimer’s type. American Association for Geriatric Psychiatry 27th Annual Meeting. Baltimore, USA (2004).
   Google Scholar
• PESKIND E, POTKIN S, POMARA N: Memantine monotherapy is effective and sage for the treatment of mild-to-moderate Alzheimer’s disease: a randomized controlled trial. J. Eur. Neuropharmacol. (2004) 14(Suppl. 3):332.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Evaluation of memantine for neuroprotection in dementia. Expert Opin. Investig. Drugs (2000) 9(6):1397-1406.
   PubMed Web of Science ®Google Scholar
• KORNHUBER J, QUACK G: Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. (1995) 195(2):137-139.
   PubMed Web of Science ®Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacology (1999) 38(6):735-767.
   PubMed Web of Science ®Google Scholar
• AMETAMEY SM, BRUEHLMEIER M, KNEIFEL S et al.: PET studies of 18F-memantine in healthy volunteers. Nucl. Med. Biol. (2002) 29(2):227-231.
   PubMed Web of Science ®Google Scholar
• FREUDENTHALER S, MEINEKE I, SCHREEB KH, BOAKYE E, GUNDERT-REMY U, GLEITER CH: Influence of urine pH and urinary flow on the renal excretion of memantine. Br. J. Clin. Pharmacol. (1998) 46(6):541-546.
   PubMed Web of Science ®Google Scholar
• PERICLOU AP, VENTURA D, SHERMAN T, RAO N, ABRAMOWITZ WT: Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann. Pharmacother. (2004) 38(9):1389-1394.
   PubMed Web of Science ®Google Scholar
• PERICLOU A, VENTURA D, RAO N, ABRAMOWITZ W: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin. Pharmacol. Ther. (2006) 79(1):134-143.
   PubMed Web of Science ®Google Scholar
• SMITH M, WELLS J, BORRIE M: Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. (2006) 20(3):133-137.
   PubMed Web of Science ®Google Scholar